

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Krithika Rajagopalan¹ · David Trueman² · Lydia Crowe² · Daniel Squirrell² · Antony Loebel¹

Published online: 11 April 2016

© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Background In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain and relapse. We conducted a cost-utility analysis of lurasidone versus aripiprazole from the perspective of healthcare services, using Scotland and Wales as specific case studies.

Methods A 10-year Markov model, incorporating a 6-week acute phase and a maintenance phase across three health states (discontinuation, relapse, death) was constructed. Six-week probabilities of discontinuation and adverse events were based on a published independent mixed-treatment comparison; long-term risks of relapse and discontinuation were from an indirect comparison. Costs included drug therapy, relapse, and outpatient, primary and residential care. Costs and benefits were discounted at 3.5 %. Utility estimates were taken from published literature, and cost effectiveness was expressed as total 10-year incremental costs and quality-adjusted life-years (QALYs).

Results Lurasidone yielded a cost saving of £3383 and an improvement of 0.005 QALYs versus aripiprazole, in

Scotland. Deterministic sensitivity analysis demonstrated that results were sensitive to relapse rates, while probabilistic sensitivity analysis suggested that lurasidone had the highest expected net benefit at willingness-to-pay thresholds of £20,000–30,000 per QALY. The probability that lurasidone was a cost-effective treatment strategy was approximately 75 % at all willingness-to-pay thresholds, with similar results being obtained for the Welsh analysis. **Conclusions** Our analysis suggests that lurasidone would provide an effective, cost-saving alternative for the healthcare service in the treatment of adult patients with schizophrenia.

Key Points for Decision Makers

Treatment of schizophrenia with atypical antipsychotics may be associated with weight gain and metabolic side effects.

Lurasidone is a recently approved atypical antipsychotic for the treatment of schizophrenia in adults in Scotland.

Lurasidone is associated with statistically significant improvements in efficacy and was generally well-tolerated in clinical studies when compared with other common atypical antipsychotics.

Lurasidone is most likely to displace aripiprazole in patients with schizophrenia at risk of weight gain and/or metabolic disease.

Lurasidone is likely to provide overall savings due to lower relapse rates and greater improvements in quality of life when compared with aripiprazole.

Electronic supplementary material The online version of this article (doi:10.1007/s40273-016-0405-0) contains supplementary material, which is available to authorized users.

✉ Krithika Rajagopalan
Krithika.Rajagopalan@sunovion.com

¹ Health Economics and Outcomes Research, Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752, USA

² DRG Abacus, Bicester, Oxfordshire, UK

1 Introduction

Schizophrenia is a chronic and disabling mental health condition resulting in progressive neurocognitive dysfunction, leading to alterations in perception, thoughts, mood and behaviour [1]. It has a lifetime risk of approximately 1 % and has a significant health, emotional and social impact on the patient, leading to social isolation, disability and dependence, unemployment and, in extreme cases, imprisonment and homelessness [2, 3]. The condition has a significant financial burden; in England, the total combined annual cost to society and the public sector was estimated to be £19 billion in 2010/11 [4]. The mainstay of current treatment for acute schizophrenic episodes, symptom reduction, and relapse prevention in patients with schizophrenia is antipsychotic medication [5]. It is recognised in numerous national and international guidelines that patients with schizophrenia should be treated with first- or second-line antipsychotics, and offered clozapine after prior failure of two antipsychotics [6–8]. The choice of antipsychotics should be based on a combination of treatment efficacy, tolerability, and patient and carer preferences [6, 7]. In the UK, current Scottish Intercollegiate Guidelines Network (SIGN) guidelines (131) recommend that olanzapine, risperidone or amisulpride should be prescribed for first-line treatment of patients with acute exacerbation or recurrence of schizophrenia, and for maintenance treatment [9].

Compounding this debilitating mental condition, comorbidities related to cardiovascular disease and metabolic disorders, such as diabetes, hypertension, metabolic syndrome, and obesity, are disproportionately prevalent among patients with schizophrenia [10]. Compared with the general population, patients with schizophrenia have almost twice the risk of metabolic syndrome (40.9 vs. 23.7 %, respectively) and diabetes (10.3 vs. 5.6 %, respectively) [11, 12], as well as an increased risk of cardiovascular disease-related mortality, with patients' life expectancy reduced by an average of 15 years [13]. The prevalence of cardiovascular risk factors is also disproportionately high among patients with schizophrenia, of whom 58 % have dyslipidaemia, 45 % have hypertension and 15 % have abnormal fasting glucose, while 68 % are obese [14].

Although the presence of some modifiable cardiovascular disease risk factors, such as an increased sedentary lifestyle, may be specifically attributable to schizophrenia, a number of atypical antipsychotics have been associated with an increased risk of weight gain and other metabolic abnormalities [15–17]. These adverse effects frequently lead to discontinuation and/or cycling between different therapies [18–21]. Schizophrenia

remains one of the most challenging disorders to treat due to a number of factors, including heterogeneity of presentation and patient response to treatment, disease-related risk of morbidity and mortality, and treatment-emergent adverse effects such as weight gain [22, 23]. For patients who are at risk of, or concerned about, weight gain, aripiprazole, haloperidol or amisulpride are recommended in SIGN guideline 131. This is supported by current National Institute for Health and Care Excellence (NICE) guidelines (CG178), which recommend that the potential risk of treatment-emergent weight gain should be considered when making treatment choices [5].

In January 2014, lurasidone, a new atypical antipsychotic, obtained marketing authorisation in Europe for the treatment of schizophrenia in adults [24]. In the UK, lurasidone has received positive recommendations for use by the Scottish Medicines Consortium (SMC) in Scotland “as an alternative treatment option in patients in whom it is important to avoid weight gain and metabolic adverse effects” and by the All Wales Medicines Strategy Group (AWMSG) as an option for use in adults aged 18 years and over [25, 26]. In five phase II and III, 12-month, double-blind, head-to-head studies, lurasidone was associated with significant improvements in symptom reduction and minimal changes in weight, body mass index, and metabolic outcomes versus placebo [27–31]. In studies where patients switched from a previous atypical antipsychotic to lurasidone, lurasidone was associated with improvements in weight and lipid levels, and demonstrated a low rate of treatment failure and high rate of study completion [32, 33]. When indirectly compared with other studies that have evaluated the efficacy and safety profile of atypical antipsychotics, such as aripiprazole, olanzapine, and quetiapine, lurasidone is associated with significant improvements in terms of weight gain, metabolic outcomes, relapse rates, hospitalisations, and rates of all-cause discontinuation [34–36].

While the clinical effectiveness of lurasidone in the treatment of schizophrenia has been demonstrated, the cost effectiveness of lurasidone versus alternative therapies remains to be established. We developed a model to evaluate the cost utility of introducing lurasidone as a treatment option for adult patients with schizophrenia from the perspective of healthcare services. In this study, we focus on Scotland and Wales as specific case studies in light of the recent SMC and AWMSG recommendations. These case studies compared the cost effectiveness of lurasidone versus aripiprazole as lurasidone is likely to replace aripiprazole as a treatment option for patients with schizophrenia.

2 Methods

2.1 Model Overview

To reflect the chronic nature of the disease, a Markov model was constructed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) (Fig. 1) to estimate the effectiveness (relapse, discontinuations, side effects and mortality) and costs for adult patients with schizophrenia. In line with previous economic evaluations [27, 30, 37], this cost-utility model assumes that treatment is initiated in a population with acute schizophrenia (acute phase), who then continue into a maintenance phase following disease stabilisation. In line with other models, a 10-year time horizon was used so that longer-term differences between treatments could be considered, and a discount rate of 3.5 % was applied to both costs and benefits [7, 38].

The model compares two alternative treatment sequences. For Scotland, current SIGN guidelines [9] state that “clozapine should be offered to service users who have treatment-resistant schizophrenia”, with treatment-resistant schizophrenia defined as “... failure to respond to an adequate trial of two different antipsychotics”. Based on this guidance, simplified treatment sequences were constructed. The first strategy consisted of lurasidone, followed by amisulpride, clozapine and, finally, an augmented clozapine strategy. The second differed from the first therapy in sequence only, which was aripiprazole.

Patients enter the model in an acute phase of relapse undergoing trials of antipsychotic agents (‘non-stable/Rx trial’ health state). Patients who have not discontinued treatment by week 6 are assumed to enter the ‘stable/adherent’ disease state the maintenance phase and are assumed initially to be on treatment. Those who have discontinued treatment at week 6 for any reason are assumed to switch therapy at this point and re-enter the non-stable/Rx trial health state to continue the process of trialling alternative antipsychotic agents. Patients may also die from any health state within the model. The 6-week endpoint for the acute phase of the model, and ongoing cycle length in the Markov model, was chosen to be consistent with the short-term studies of lurasidone [27, 37].

Individuals in the ‘stable/adherent’ health state in the maintenance phase are further subject to risks of all-cause discontinuation, relapse and death. Individuals discontinuing treatment in the maintenance phase are assumed to receive no therapy, and reside in the ‘stable/non-adherent’ health state until the onset of relapse, at which point they enter the ‘relapse’ health state. Relapse is considered to be treated either in an inpatient setting or at home, with treatment administered via the crisis resolution home treatment teams (CRHTTs), and patients who relapse are assumed to discontinue current therapy and switch to the next therapy in the sequence.

Reductions in health-related quality of life (HRQoL), as well as costs associated with weight gain (defined as a

Fig. 1 Model schematic




Table 1 Summary of efficacy and safety data used in the model

	Therapy	
	Lurasidone	Aripiprazole
Acute phase model inputs		
All cause discontinuation [OR] (95 % CI) ^a	0.77 (0.61, 0.96)	0.61 (0.51, 0.72)
EPS [OR] (95 % CI) ^a	2.46 (1.55, 3.72)	1.20 (0.73, 1.85)
Weight gain [%] ^b	5.22	7.04
Maintenance phase model inputs		
Relapse [HR] (95 % CrI) vs. quetiapine	0.699 ^c (0.303, 1.244)	1.029 ^d
Discontinuation [HR] vs. quetiapine	0.723	0.98

CI confidence interval, *CrI* credible interval, *EPS* extrapyramidal symptoms, *HR* hazard ratio, *OR* odds ratio

^a Calculated vs. placebo [34]

^b Probability of weight gain $\geq 7\%$ at week 6 estimated assuming a common standard deviation, assuming mean change in weight is normally distributed

^c From study D1050234, as reported Loebel et al. [37]

^d Calculated by indirect comparison with quetiapine [36]

$\geq 7\%$ change in weight), presence of extrapyramidal symptoms (EPS) and diabetes, were applied, as experienced by patients in the model. Weight gain was assumed to persist while on treatment; EPS was assumed to persist for 3 months from the start of treatment, in line with the economic evaluation in NICE CG82, and incurred a one-off HRQoL decrement and cost; diabetes incidence occurred cumulatively over time from any state.

The main outcome measure of the analysis was the incremental cost-effectiveness ratio (ICER) for lurasidone versus aripiprazole, reported as cost per quality-adjusted life-year (QALY) gained. The electronic model has previously been reviewed by economists from UK national health technology assessment bodies [26, 39], and all clinical data and the model design were validated by an independent expert advisory board comprising nine clinicians in the UK.

2.2 Data Used in the Model

2.2.1 Clinical Efficacy

A 2013 independent systematic review and mixed treatment comparison (MTC) of atypical antipsychotics by Leucht et al. [34], including lurasidone and aripiprazole versus placebo, was used to inform estimates of short-term efficacy (probability of all-cause discontinuation) in the acute phase. Since the systematic review and MTC considered the relative effectiveness of lurasidone and aripiprazole versus placebo, it was necessary to establish an absolute placebo effect in order to estimate absolute effects for these therapies [27]. Model data inputs for all-cause discontinuation, EPS and weight gain for the acute phase are shown in Table 1, and a summary of all model input

data is provided in Online Resource 1. Weight gain was considered clinically relevant if the patient experienced $\geq 7\%$ change in weight (measured in kilograms) from baseline. The independent MTC meta-analysis did not report long-term clinical outcomes, and no other comparative clinical data were available for lurasidone versus aripiprazole. Therefore, for the maintenance phase of the model, long-term risks of relapse and all-cause discontinuation for lurasidone were taken from a 12-month, randomised, double-blind, active-controlled study versus quetiapine [37]. To inform aripiprazole data, the quetiapine arm of the lurasidone trial was then compared with aripiprazole via an adjusted indirect comparison (via the Bucher method using olanzapine as the common comparator [40]), with relapse data taken from a 52-week, open-label extension to a 26-week comparison of aripiprazole with olanzapine [41], and from a 12-month, open-label extension study of quetiapine versus olanzapine [42]. This approach ensures that the relative effect of aripiprazole versus lurasidone can be calculated by discounting for the effect of the common comparator, quetiapine. To clarify, the adjusted indirect comparison of aripiprazole (A) computed an effect relative to quetiapine (B) by comparing aripiprazole (A) versus olanzapine (C) and quetiapine (B) versus olanzapine (C). In the absence of a common definition of relapse available across studies, all-cause hospitalisation was considered a proxy for relapse in the estimation of relative effects. We believe it is reasonable to consider relative treatment effects for all-cause hospitalisation as a proxy for relative treatment effect for relapse since hospitalisation is one of the variables measuring the composite endpoint ‘relapse’ in all clinical trials. For example, the definition of relapse provided by Loebel et al. [37] is “... the earliest occurrence of any of the

following 3 criteria: (1) worsening of $\geq 30\%$ in the PANSS total score from Day 42 of the initial acute treatment study and a CGI-S ≥ 3 ; (2) re-hospitalisation for worsening of psychosis; or (3) emergence of suicidal ideation, homicidal ideation and/or risk of harm”.

While the cause is unknown, the prevalence of diabetes in patients with schizophrenia ranges from 11.3 to 22.3 %, and therefore the risk of developing diabetes was included in the model [43–45]. To include the effect of diabetes in the current analysis, an approach similar to that of the NICE CG82 was used. The relative effect of developing diabetes was equal to the relative effect of experiencing weight gain. Cardiovascular events were not considered since including them would potentially lead to double-counting of the consequences of diabetes.

Mortality was based on published life tables of the general population, and adjusted to reflect the increased risk of mortality in patients with schizophrenia [46].

In the acute phase, patients cycled through a number of treatment regimens until they reached a stable disease state. The efficacy and safety data of subsequent therapies (amisulpride, clozapine, and augmented clozapine) were taken from Leucht et al. [34]. Data for augmented clozapine were assumed to equal the data for clozapine. In the absence of data, the risk of relapse and discontinuation versus quetiapine were assumed to be equal to quetiapine in the maintenance phase; the risk of relapse and discontinuation were assumed to remain constant throughout subsequent lines of therapy.

2.3 Health-State Utilities

A systematic review of health state utility values and HRQoL evidence in schizophrenia was performed. Electronic database searches were undertaken in November 2012, and conferences were searched between 2010 and 2012. Of the identified literature, those that were used in the development of the NICE guidelines were deemed to be the most appropriate to a UK clinical setting and were subsequently used to inform model estimates. To consider the impact of schizophrenia on patient HRQoL, utility scores reported in NICE CG82 and Lenert et al. were applied to patients in the stable and relapse health states [7, 47]. Lenert et al. derived utility weights using a convenience sample of the general population employing a standard gamble approach [47]. Disutilities associated with clinically relevant weight gain and EPS (expressed as percentage reductions in the utility score for stable disease) were taken from the same sources. Disutility for diabetes was not presented in NICE CG82; for this adverse event, an absolute utility decrement observed between schizophrenia with diabetes and stable schizophrenia of 0.15 was

Table 2 Health state utility values used in the economic model

State	Value	Source
Stable	0.799	NICE CG82 [38]/Lenert et al. [47]
Relapse	0.670	
Weight gain	0.959 % ^a	
EPS	0.888 % ^a	
Diabetes	0.150 ^b	Estimated from Briggs et al. [48]

EPS extrapyramidal symptoms, NICE National Institute for Health and Care Excellence

^a Percentage decrement applied to utility value for stable schizophrenia

^b Absolute decrement in utility

assumed from the values presented by Briggs et al. [48] (Table 2).

2.4 Costs

Cost assumptions were based on those in NICE CG82 [7] and were updated with current estimates or adjusted to 2013/14 costs using the Hospital Pay and Prices Index [49]. All costs were presented to an advisory board consisting of five psychiatrists and four pharmacists, and country-specific data were used where available. Costs included pharmacological therapies, adverse events, switching therapies, and outpatient, primary and community care costs related to general management of care for patients with schizophrenia, relapse, and residential care (Table 3). Individual costs for outpatient, primary and community care costs are reported in Online Resource 2.

List prices for pharmacological therapies were taken from the Monthly Index of Medical Specialities [50]. It was estimated that patients with schizophrenia receiving aripiprazole would require a once-daily dose of 15 mg based on UK prescribing data [21]. For lurasidone, the assumed once-daily dose was 40 or 80 mg, based on data used for the World Health Organization Anatomical Therapeutic Chemical application (data on file). Adverse event costs included those associated with EPS and weight gain. Treatment for patients with EPS was based on 100 % of patients receiving procyclidine (5 mg/day for 3 months) and one psychiatrist outpatient visit, while treatment for weight gain consisted of the cost of two general practitioner visits and three dietetic outpatient contacts based on 100 and 20 % of patients receiving these services, respectively. Outpatient, primary and community care costs were all adjusted to 6-week costs to fit the model cycle length. Cost of relapse was the combined cost of acute hospital admissions and CRHTT, assuming 30 and 70 % of patients receiving these services, respectively, and based on expert clinical opinion provided at the lurasidone advisory board. The mean

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.